4Watson MW, Jaksic A, Price P, et al. Interferon-gamma response by peripheral blood mononuclear cells to hepatitis C virus core antigen is reduced in patients with liver fibrosis. J Infect Dis, 2003,188(10): 1533-6.
5Musch E, Malek M, Chrissafidou A. Severe exacerbation of chronic hepatitis B during therapy with corticosteroids and lamivudine therapy and successful short-term combination therapy with interferon-beta and interferon-gamma. Z Gastroenterol, 2003,41(5):42
6Hann HW, FontanaRJ, WrightT, et al. AUnitedStates compessionate use study of lamivudine treatment in nontransplantation candidatea with decompenseted hepatitis B virus-related cirrhosis. Liver Transpl, 2003,9(1) :49-56.
7Saruc M, Ozden N, Turkel N, et al. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patiants with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci,2003,92(7): 1386-95.
8Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat,2004 , 11 (2): 97-107.
9Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in norresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gestroenterol, 2003, 17 ( 8 ): 479-82.
10Munoz R, Castellano G, Fernandez I, et al. A pilot study of betainterferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon. J Hepatol, 2002,37 ( 5 ): 655-9.
